GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » Profitability Rank

Lupin (BOM:500257) Profitability Rank : 7 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lupin Profitability Rank?

Lupin has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Lupin's Operating Margin % for the quarter that ended in Mar. 2024 was 11.02%. As of today, Lupin's Piotroski F-Score is 8.


Competitive Comparison of Lupin's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lupin's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Lupin's Profitability Rank falls into.



Lupin Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Lupin has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Lupin's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=5396.6 / 48951.1
=11.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Lupin has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Lupin Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -6.4%.

4. Consistency of the profitability

5. Predictability Rank


Lupin Profitability Rank Related Terms

Thank you for viewing the detailed overview of Lupin's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin (BOM:500257) Business Description

Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400 055
Lupin Ltd is a specialty and generic drug manufacturing company. The company's global formulations business develops and delivers a wide range of branded and generic formulations across the globe. The operations of the company are limited to one segment, namely pharmaceuticals and related products. The company also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India.

Lupin (BOM:500257) Headlines

No Headlines